Extension of Victorian Government RDTI Loan Facility
Filed with ASX · · 3 pages · English
In the deck
Earlier from AdAlta
- Institutional investment to pursue strategic initiatives
- SYNBV MoU Webinar presentation
- SYNThesis BioVentures MoU for cellular immunotherapies
- Corporate Presentation
- Positive AD-214 Phase I extension study results
Later from AdAlta
- Cellular immunotherapy manufacturer secured - Cell Therapies
- $1.9 million raised from exercise of 1ADOA options
- Transaction, investment facility update
- FY24 RDTI Refund Received $1.77m
- AD-214 clinical advisory board
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta